Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Stemline Therapeutics Inc Announces Pricing Of Initial Public Offering Of 3,317,644 Shares Of Common Stock


Monday, 28 Jan 2013 07:52pm EST 

Stemline Therapeutics Inc announced the pricing of its initial public offering of 3,317,644 shares of its common stock offered at a price to the public of $10.00 per share. The gross proceeds to Stemline from the initial public offering are expected to be $33,176,440, before underwriting discounts and commissions and other offering expenses. Stemline has granted the representative of the underwriters a 45-day option to purchase up to 497,647 additional shares of common stock from Stemline to cover over-allotments, if any. The shares are expected to begin trading on the NASDAQ Capital Market under the symbol STML on January 29, 2013. The offering is expected to close on January 31, 2013. Aegis Capital Corp. is acting as sole book-running manager for the offering. Feltl and Company, Inc. and Sunrise Securities Corp. are acting as co-managers for the offering. 

Company Quote

13.21
0.47 +3.69%
20 Oct 2014